Table 2.

Univariate analysis of factors potentially associated with grade III-IV aGVHD in 106 DCBT recipients

Variable	N	Day 180 grade III-IV aGVHD, % (95% CI)	P
Age, y
0-15	14	21 (5-46)	.921
≥16	92	21 (13-30)
Conditioning
Myeloablative	80	20 (12-29)	.764
Nonmyeloablative	26	23 (9-41)
Infused total CD3+ cell dose
≤7.74 × 106/kg	55	26 (15-38)	.170
>7.74 × 106/kg	51	16 (7-27)
Dominant unit-recipient 6 allele HLA match
Worse HLA match: 2-3/6	28	32 (16-50)	.077
Better HLA match: 4-6/6	78	17 (9-26)
ST2 level, ng/mL
Low: ≤33.9	56	13 (5-23)	.024
High: >33.9	50	30% (18-43)